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Background: Everolimus-eluting stents (EES) were superior to paclitaxel-eluting stents (PES) for de-novo coronary artery disease. No data are 
available comparing these two drug-eluting stents (DES) in patients with DES restenosis and bare-metal stent (BMS) restenosis.
Methods: 215 patients with DES or BMS restenosis were consecutively treated with PES and EES implantation. Dual antiplatelet therapy was 
prescribed for 6 months. Primary objective was in-stent late loss at 6 months. Patients were clinically followed for 24 months.
Results: Patients were treated with PES (N=116) or EES (N=99). In-stent late loss was similar with 0.20±0.39 mm for EES and 0.19±0.32 mm for 
PES (P=0.29). Binary angiographic restenosis rate for the total segment was 18% for both groups. Multivariable regression analysis for in-stent late 
loss revealed length of stented segment (p=0.014) and MLD post-PCI (p<0.01) as significant predictors for in-stent late loss. With EES and PES 
in-stent late loss was lower in patients with BMS restenosis versus DES restenosis (ns). Clinical follow-up was performed after 12 and 24 months. 
There was one late stent thrombosis after 109 days in the EES group resulting in a late stent thrombosis rate of 1.0% for EES versus 0.0% for PES. 
No acute or subacute stent thrombosis was observed. At 12 months, major adverse cardiac event rate was 7% (N=7/99) with EES compared with 
9% (N=10/116) with PES. There was no statistical difference between groups (EES vs. PES) with respect to the occurrence of cardiac death (1.0% vs. 
2.6%, p=0.39), target vessel related myocardial infarction (4.0% vs. 0.9%, p=0.12), or need for re-PCI (2.0% vs. 4.3%, p=0.35) or CABG (0% vs. 0.9%, 
p=0.35). After 2 years there was no difference in MACE or repeat revascularization (8.1% vs. 10.3%, ns), respectively.
Conclusions: In this observational registry with 24 months clinical follow-up EES compared with PES implantation did not result in angiographic or 
clinical differences for treatment of BMS and DES restenosis.
